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Abstract
This manuscript summarizes current thinking on the value and promise of evolving circulating tumor cell (CTC)
technologies for cancer patient diagnosis, prognosis, and response to therapy, as well as accelerating oncologic
drug development. Moving forward requires the application of the classic steps in biomarker
development–analytical and clinical validation and clinical qualification for specific contexts of use. To
that end, this review describes methods for interactive comparisons of proprietary new technologies, clinical trial
designs, a clinical validation qualification strategy, and an approach for effectively carrying out this work through a
public-private partnership that includes test developers, drug developers, clinical trialists, the US Food & Drug
Administration (FDA) and the US National Cancer Institute (NCI).
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Introduction
The Foundation for the National Institutes of Health
(FNIH) Biomarkers Consortium is a public-private bio-
medical research partnership that promotes the develop-
ment and qualification of promising biomarkers for the
prevention, early detection, diagnosis and treatment of
disease. Consortium partners include patient advocates,
clinical researchers from academia and industry, industry
members from both therapeutic and diagnostic industries,
the NCI, and the FDA. The Cancer Steering Committee
(CSC) of the Biomarker Consortium focuses specifically
on research activities to further improve treatment for
patients with cancer through the use of biomarkers in
drug development and in the field of personalized medi-
cine. To this end, the CSC is currently sponsoring several
imaging and other cancer biomarker studies.
A particular goal of the CSC is to identify new tech-
nologies with the potential to contribute to biologically
informed drug development and clinical medicine. One
such area is the emerging field of CTC detection and
analysis. The potential implications of successful devel-
opment of appropriate technologies are very large, and
exciting new technologies are under development. How-
ever, many questions remain unanswered regarding the
biology of CTCs, how best to enumerate and characterize
them and the path to regulatory and general clinical
acceptance for technology platforms currently under
development.
Because of its composition and the skill sets and activ-
ities of its member organizations, the Biomarkers Con-
sortium is uniquely positioned to help answer some of
these important questions. To this end, the Consortium
sponsored a workshop on qualification and validation of
CTC assays. This paper summarizes not only the discus-
sions from that meeting, but the outcome of a series of
further deliberations by a CTC Working Group (CWG)
convened by the CSC. The results will be the basis of a
series of clinical studies to be conducted by the CSC to
help answer these CTC questions, and move the field
forward.
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CTCs: A background
CTCs have been defined as cancer cells of solid tumor
origin found in the peripheral blood. It is generally
thought that these cells detach from primary or secondary
tumors of patients with advanced cancer prior to detec-
tion in the circulation. CTCs are considered very rare,
with an estimated frequency of one in 100 million to one
in a billion blood cells [1,2]. CTCs have been detected in
the peripheral blood of patients with advanced stages of
most types of solid tumor cancers, and their presence
may represent the hematogenous phase of metastasis
since CTCs are often not seen until tumors have achieved
neovascularization [1,3]. However, CTCs have also been
detected in the peripheral blood of patients with localized
cancers, which may be indicative of increased risk of pro-
gression to metastatic disease [4-10], and very early dur-
ing tumor development, even at a pre-malignant stage in
a pancreatic cancer model [11].
Certain phenotypic characteristics have been utilized
consistently to identify CTCs in the peripheral blood.
CTCs were initially characterized as non-leukocytic,
nucleated cells that are typically epithelial in origin, and
maintain significantly larger diameters and total mem-
brane surface areas than normal blood cells. However, the
morphological features of CTCs are now known to be less
clearly defined, and may vary by disease, disease stage (at
the time of diagnosis), or disease state (e.g., pre- vs. post-
treatment setting). In addition, a significant number of
CTCs may lose their epithelial antigens and express the
phenotypic markers of epithelial-mesenchymal transition
(EMT), a phenotypic change that is thought to be an im-
portant feature in the metastatic process that allows
tumor cells to travel to the site of metastasis formation
without being affected by conventional treatment [12-15].
It is unknown if CTCs represent more aggressive cells
than those in the tumor of origin. However, phenotypic
assessments to date suggest that at least some subset of
CTCs may represent viable metastatic precursor cells
capable of initiating a clonal metastatic lesion [12-15]. In
this context, the importance of tumor-stroma interactions
in generation and/or maintenance of the cancer “stem”/
tumorigenic cell status (tumor plasticity) should not be
underestimated. The resulting molecular and phenotyp-
ical alterations are complex and may vary by cancer (sub)
type, over time, and by stage of the disease (e.g., [16]).
These complexities introduce additional challenges for
interpreting CTC analysis results.
The analytical methods/assays used and the degree of
their validation will be critical to establishing a common
set of criteria describing CTCs. Progress in use of differ-
ent CTC-related platforms for specific applications in
the clinic (beyond CTC enumeration being monitored at
multiple time points during the course of patient’s treat-
ment) depends on establishing such criteria, keeping in
mind how well the malignant features of detectable cir-
culating cells are defined, and in the context of other
molecular findings, to what extent identified CTCs could
be helpful in detecting emerging resistance to treatment.
This latter aspect could be critical for early modification
of therapy, thus contributing to personalized health care.
A recent insight derived from CTC analyses has
involved finding clusters of CTCs in the circulation of
patients with advanced cancer [17-19]. It is not clear
whether these aggregates are artifacts of sample proces-
sing, or if the detection of clusters has previously been
limited by the technologies used for CTC isolation, most
of which are purification approaches likely to disrupt
clusters [20]. Early studies suggest that CTC clusters
may be relatively protected from cell death and the
harsh environment and shear stresses of the vascular cir-
culation; they may also be clinically significant; particu-
larly the number, size, or composition of the clusters
[17-19,21-23]. The presence of clusters may be a better
biomarker for increased metastatic potential than single
CTCs [17,18,22].
Major questions to be answered concerning CTCs
The phenotype(s) of CTCs has not been fully defined. It
is currently accepted that CTCs are morphologically
EpCAM+, cytokeratin (CK)+, and CD45−. However,
there is evidence that these cells can also occur in
patients with benign diseases of the colon [24] and other
phenotypes may be present in the blood of metastatic
cancer patients, including CD45+, CK+ cells. It has been
shown that these double-positive cells can be the result
of long storage, and probably represent artifacts (which
is consistent with evidence that that CK +, CD45 + cells
do not have prognostic impact [25]). Further, while
CTCs are thought to seed metastatic sites from a pri-
mary tumor, there is known discordance between tumor
tissue biomarker expression and CTC biomarker expres-
sion, as well as heterogeneity of biomarker expression
among multiple metastatic sites [26-28]. This suggests
that CTCs from metastatic sites can in themselves seed
new sites (e.g., [29]). In addition, recent studies have
shown that CTC markers may change over the course of
therapy (e.g., [30]).
Identification of predictive biomarkers in CTCs has the
potential to become a breakthrough in cancer diagnostics
and drug development. There are many sensitive and reli-
able tools that may be used for the characterization of
CTCs, including immunocytochemistry, immunofluores-
cence, laser scanning, fluorescence in situ hybridization
(FISH), and polymerase chain reaction (PCR) techniques
[9,31-33]. However, statistically meaningful numbers of
CTCs may need to be isolated in order to characterize the
heterogeneity, determine cellular origin (primary vs.
metastatic tumor), and evaluate CTC response (signalling,
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proliferation, and apoptosis) after therapeutic interven-
tions. Through initiatives such as the NCI Alliance in
Nanotechnology in Cancer, Clinical Tumor Proteomics
Analysis Consortium, The Cancer Genome Atlas, and the
Physical Sciences in Oncology Centers, the NCI Center
for Strategic Scientific Initiatives (CSSI) is contributing to
this effort by providing the community with large-scale,
reproducible genomic, epigenomic, and proteomic signa-
tures, and with advanced, robust technologies to examine
such signatures at high-throughput and high-resolution.
The biomarker development process and development of
CTCs as biomarkers
Validated CTC assays and CTCs qualified as biomarkers
of cancer prognosis and response to therapy through the
FDA Center for Drug Evaluation (CDER) process have
the potential to improve the diagnosis and care of cancer
patients, one of the goals of personalized medicine. The
FDA defines a validated biomarker assay as an analytical
test system with well-established performance character-
istics and for which there is an established scientific
framework or body of evidence that elucidates the
physiologic, toxicological, pharmacologic, or clinical sig-
nificance of the test results [34]. For qualification, the
results of biomarker measurements are expected to have
met evidentiary standards within specific contexts of use
linking the biomarker result with clinical measurements,
and to be reliable for specific interpretations and appli-
cations in drug development and clinical and regulatory
decision-making.
There are several ways by which biomarkers gain ac-
ceptance for regulatory decision making through the
FDA. On a case-by-case basis, data on candidate biomar-
kers that are either used to make decisions in clinical
trials or are being considered as a biomarker in human
safety studies may be submitted to an investigational
new drug application (IND), new drug application
(NDA), or biologics license application (BLA) [34]. Al-
ternatively, a test for a biomarker that will be required
to support the dose selection, safety, or effectiveness of a
drug, and that a sponsor will thus integrate into the drug
development program, may be submitted as part of a co-
development of drug and test combination (i.e., as a
companion diagnostic) [35].
Finally, FDA CDER has developed a Biomarker Quali-
fication program as an outgrowth of the Critical Path
Initiative to capture consensus on the context of use and
supporting data for biomarkers, and to encourage the
development of new biomarkers [34]. Through this pro-
gram, biomarker qualification is defined as “a conclusion
that within a carefully and specifically stated ‘context of
use’, the biomarker has been demonstrated to reliably
support a specified manner of interpretation and appli-
cation in drug development”. Once qualified, biomarkers
can be used in the qualified context in INDs, NDAs, and
BLAs; CDER regulatory reviews in all offices and disci-
plines will adhere to the qualification decision. However,
an in vitro diagnostic device, e.g., a CTC test, needed to
measure a qualified biomarker is required to be cleared
by the FDA Center for Devices and Radiological Health
(CDRH) with data supporting the analytical and clinical
performance if it is to be used clinically as a diagnostic
test, i.e., to inform patient management.
The voluntary process of qualification is intended for
biomarkers that will be used as drug development tools
[34]. Since public knowledge and access are often essen-
tial to the process, collaborative groups such as the Bio-
markers Consortium can be useful sources of candidate
biomarkers. The process itself provides a framework for
interactions between CDER (and often other centers
within FDA) and sponsors, with CDER guidance towards
the compilation of comprehensive evidence to support
the end result of qualification. The interactions include
initial evaluation, interactive consultation and advice,
and final in-depth review.
An analytically validated assay for the biomarker is a
prerequisite for qualification, since the stability, accur-
acy, and reproducibility of the measurement will be crit-
ical to demonstrating utility. Candidate CTC-based
biomarkers include the number and/or molecular sub-
classification of target cells, and among the assays of
interest are those that measure these parameters. Cri-
teria for assessing the analytical validity of clinical assays
have been published by the Clinical and Laboratory
Standards Institute (CLSI), FDA’s Office of In Vitro Diag-
nostics, and other groups [36]. Some considerations for
evaluating the analytical and clinical validity of CTC
assays are listed below, and reliability of data sources for
determining clinical validity are listed in Table 1.
CTC assay analytical validation considerations include
the following:
Pre-analytic Variables Controlled
 Materials at study site, e.g., sample collection tubes,
shipping containers
 Materials at analytic laboratory, e.g., assay-specific
kit (w/instructions for use, reagents, buffers,
controls, etc.), additional equipment (centrifuge, test
tubes, micropipettes, vortex mixer, etc.)
 Reagent storage conditions (temperature, time, etc.)
 Specimen collection, e.g., timing of specimen
collection relative to study treatments and
procedures, phlebotomy procedure (patient
positioning, needle size, blood draw site, sample size
and number of samples, collection tube, tube
inversion for clot prevention)
 Specimen handling e.g., storage time and
temperature, shipping time, etc.
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Analytic Variables Controlled
 Type of analysis (enrichment/enumeration/
molecular characterization of target cells)
 What is the range of specimens tested?
 Sensitivity of assay (enrichment/enumeration/
molecular characterization of all cells)
 Specificity of assay (enrichment/enumeration/
molecular characterization of only target cells)
 How often does the assay give a useable result?
 How similar are the results with repeated
measurements?
 What are the analytical range, reproducibility, and
clinical applicability of the test?
 How similar are the results obtained within the
same or in multiple laboratories using the same or
different technology?
 Assay-specific controls should be run each day of
analysis or when a new assay lot is used to check
overall performance, including instrument, reagents,
and operator technique
 Assay-specific controls should be run regularly
(monthly or quarterly) to show performance at the
lower limit of analysis
 Assay-specific samples should be run semi-annually
to document the lower limit of quantitation
 Calibration/calibration verification (at least semi-
annually)
Post-analytic Variables
 All participating laboratories in the same study
should use common controls to document
continuously across laboratory performance.
 Splitting samples across laboratories prior to the
study is recommended to document assay
performance across laboratories.
CTC assay clinical validity considerations include the
following:
Assay Characteristics
 Clinical sensitivity and specificity of assay
 Are there methods to resolve clinical false positive
assay results in a timely manner?
Disease Characteristics
 Prevalence (how often are the target cells detectable
in the study population?)
 What is the relationship between detectable target
cells and the study disease?
 Positive predictive value (what is the probability that
a positive assay result means that the subject has the
target disease?)
 What are the genetic, environmental, or other
modifiers for detection of the target cells?
A working group formed at the NCI–European Organ-
isation for Research and Treatment of Cancer (EORTC)
First International Meeting on Cancer Diagnostics con-
vened in Nyborg, Denmark, in July 2000 created a set of
criteria for high quality reporting of biomarker studies
[37]. The guidelines evaluate study design, methods, and
analyses; and provide suggestions for the types of data
elements that should be reported. These guidelines will
be useful in obtaining data for evaluating and comparing
CTC assays.
During clinical validation prospective clinical studies
may be designed to show evidence of the link between
the biomarker being measured and the specific biologic
process or clinical outcome. Sometimes, links between a
candidate biomarker and a biologic process or clinical
outcome can be supported by examining retrospectively
collected data or specimens for which the process or out-
come in question is known, but this will generally provide
only exploratory information that will need prospective
confirmation. Retrospective collections of samples are not
expected to contain stable/viable/molecularly unaltered
CTCs, due to the labile nature of live cells once removed
from the body.
Table 1 Evaluation Criteria for Sources of Clinical Assay
Performance Data
Qualitative Rankings of Data Sources and Study Designs
Most Reliable Collaborative studies that use large panels of
well characterized samples; summary data from
well-designed external proficiency testing schemes;
inter-laboratory comparison programs
Reliable Other data from proficiency testing schemes,
well-designed peer-reviewed studies, and
expert panel-reviewed FDA summaries
Less Reliable Less well designed peer-reviewed studies
Least Reliable Unpublished and/or non-peer reviewed
research; clinical laboratory, or manufacturer
data; studies on performance of
the same basic methodology, but used to test
for a different target
Criteria for Assessing the Internal Validity of the Studies Used to
Obtain Data
• Adequate descriptions of the assay platform and test procedures,
including the reproducibility of test results, quality control measures,
and comparison to a “gold standard” reference assay.
• Samples representative of the study population, blinded testing and
interpretation.
• Data analysis including point estimates of sensitivity and specificity
with 95% confidence intervals, and sample size/power calculations.
• Studies graded as convincing, adequate, or inadequate based on their
ability to provide confident estimates of analytic sensitivity and
specificity using intended sample types from representative populations.
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Potential contexts of use for CTCs
Many potential clinical contexts of use exist for CTCs.
Detection of CTCs may potentially be used to establish a
diagnosis, as an alternative to invasive biopsies for early
detection of metastatic tumor tissue, and for monitoring
cancer patients [21,38-40]. CTCs also have potential for
investigation of heterogeneity in biomarker expression
between primary tumors and distant metastases, as well
as among multiple metastatic sites [9,26-28,30,41]. Par-
ticularly interesting to the Biomarkers Consortium, the
numbers and characteristics of CTCs may be prognostic
for survival or predictive of response to cancer therapy
in general or of response to a specific therapy. Moreover,
changes in CTCs during the course of therapy may serve
as biomarkers of treatment response or resistance.
Assays that enumerate or report the number of CTCs
in a whole blood sample of a patient with advanced can-
cer have been shown to be prognostic for survival [42-
44]. CTC enumeration via the Veridex CellSearchTM
System is FDA-cleared for use as an aid in monitoring
patients with metastatic breast, colorectal, and prostate
cancers (FDA, CDRH). The presence prior to treatment
of ≥5 CTCs in a 7.5 ml sample for metastatic breast and
prostate cancers, and ≥3 CTCs for colorectal cancer is
associated with decreased progression-free and overall
survival, and is prognostic, regardless of therapy used.
Recent studies have also shown the potential utility of
the CellSearchTM assay for monitoring patients with
melanoma, urothelial, and lung cancer [45-48].
Beyond enumeration, molecular profiling of CTCs has
the potential to provide predictive information to guide
the selection of therapy [49,50]. For example, although
several studies have not seen this correlation [9,41,50],
other studies indicate that there is concordance for
human epidermal growth factor receptor 2 (HER2) gene
status between primary breast cancer tumors and CTCs.
This suggests that targeting patients with HER2-positive
(HER2+) CTC test results with the anti-HER2 antibody
trastuzumab may significantly improve clinical outcomes
for HER2+ breast cancer (e.g., [51]). CTC characterization
may also aid in accelerating drug development and ap-
proval, since the focus of many current oncology drug
discovery efforts is developing targeted therapies against
signalling proteins implicated as important drivers of ag-
gressive tumor growth and survival. A key step in the suc-
cessful clinical development of such agents is the
identification of responsive or resistant patient populations
with predictive biomarkers for these therapies. The study
of detailed molecular signatures for individual CTCs may
also provide leads in new drug discovery by assessing the
markers unique to progression so that relapsing patients
can be treated for their current “molecular disease”.
As cancer cells can be more frequently sampled in cir-
culation than through tumor biopsy, characterization of
CTCs over time can provide an opportunity to better as-
sess dynamic physiologic responses to treatment. Measur-
ing CTCs sequentially during the course of therapy may
reveal tumor evolution under therapeutic “natural selec-
tion” and permit the identification of biologic determi-
nants of drug resistance or progression (e.g., secondary
mutations) [9,52,53]. In this regard, evolutionary biolo-
gists working with the NCI Office of Physical Sciences-
Oncology, are discovering instantaneous and long-term
responses in more than 150 patients by examining robust
data generated by high-content CTC platforms using
~2500 samples collected at regular timed intervals.
Post-therapy changes in CTCs might be an easily ac-
cessible intermediate point-of-response efficacy. Further,
a number of cases have shown that CTC numbers change
prior to changes being seen with anatomical imaging, and
that CTC analysis may be a more robust surrogate of sur-
vival than anatomical imaging; so CTCs potentially may
have more utility in the clinical setting [9,10,54]. CTC
evaluation might ultimately be used as a surrogate meas-
urement of clinical benefit and therefore an endpoint in
clinical research.
A major challenge in processing and analyzing CTCs
is their low concentration in blood. For example,
detailed standard protocols for controlling pre-analytic
variables associated with collection and handling of
blood samples are likely needed to ensure reproducibility
of assay results (see below under Standards). A wide
range of assay platforms is currently under development
for analysis of CTCs [29,32,50,55]; the developers seek
to optimize both sensitivity and specificity for detecting
CTCs and to avoid generation of artifacts from extensive
processing. Whole blood sample enrichment for CTCs
generally involves density gradient centrifugation, immu-
nomagnetic isolation, microfluidics, or some combin-
ation of techniques. CTC enumeration platforms are
generally image-based approaches using immunocyto-
chemistry or laser scanning cytometry, and CTC
characterization techniques are typically nucleic acid or
protein-based molecular assays, imaging, or a combin-
ation of molecular and imaging methods. As suggested
by the background discussion above, each assay platform
will likely have strengths and weaknesses in evaluating
various aspects of CTCs. For instance, assays using
immunomagnetics with anti-EpCAM antibodies are very
efficient at enriching for epithelial cells but may miss
cancer cells that have undergone EMT.
A number of promising techniques reported in the past
few years use microfluidic devices to isolate CTCs from
whole blood. In addition to enabling detection of CTCs
in small blood samples, key design features of these tech-
niques are flow patterns to optimize exposure of blood
cells to the CTC detection method (often anti-EpCAM
antibodies) and to minimize nonspecific leukocyte
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binding, as well as provision of platforms for molecular
characterization of the captured cells. For example,
among the microfluidics-based devices is one in which
blood is pumped across a silicon-etched chip containing
thousands of microposts fitted with anti-EpCAM anti-
bodies. EpCAM-positive cells attach to the microposts
and are then analyzed using dyes and imaging [7]. An
enhanced version of this CTC Chip uses microvortices in
a herringbone pattern to increase the number of interac-
tions between CTCs and the antibody-coated chip sur-
face [17]; DNA from cells captured on the chip are
extracted and analyzed for specific molecular targets
[52]. Another microfluidics device contains sinusoidal
micro channels coated with anti-EpCAM antibodies to
capture CTCs; the captured cells are detached from the
micro channels using trypsin and passed through a con-
ductivity sensor on the device for enumeration [56]. Spe-
cific to prostate cancer, a microfluidic device with a
three-dimensional flow pattern has been described that
uses anti-prostate specific membrane antigen (PSMA)
antibody to capture CTCs (PSMA+, CD45− cells) [57].
Captured cells are fixed on the device and stained for
PSMA, EpCAM, and presence of a nucleus; CTCs are
enumerated with the aid of confocal microscopy. The
captured cells can be made permeable to enable detec-
tion of intracellular antigens (e.g., TMPRSS-ERG fusion
protein) or lyzed for RNA extraction. Table 2 lists some
of the more widely publicized CTC assays and assay plat-
forms being developed for commercial use, including
those with microfluidic and microarray technology.
Selection of CTC technologies for clinical development
One of the goals of the Biomarkers Consortium Work-
shop was to bring together experts in the field of CTC
research to identify and implement practical ways of
comparing the performance of the most promising CTC
assay technologies at equivalent levels of development as
an initial step in clinical validation. This work, viewed as
a preliminary step, was necessary to determine the value
of a particular technology for inclusion in clinical trials.
Discussions from the workshop and recommendations
from subsequent CWG meetings are summarized below.
Practical application
Selected CTC assays could range from relatively low
technology immunoassays for enumeration to more
advanced technology platforms for molecular analysis,
but priority should be given to examination of technolo-
gies with robust analytical validation and potential for
providing data to address the key questions regarding
biology and clinical significance of CTCs.
Clearly, different technologies may be more or less ap-
propriate for specific applications, and more than one
assay may be required for different contexts of use in a
given patient. For example, a technology optimized for
enumeration might not be optimal for providing enriched
or purified CTC populations for detailed biological
characterization. Therefore, no simple generalization can
be made about the “ideal CTC technology”. Nevertheless,
general comments can be made regarding characteristics
which each technology should possess.
For example, the CTC technologies selected for evalu-
ation should be ready to use in a clinical laboratory set-
ting (see Table 3). Standard reference materials for the
assay should be available and readily accessible by labora-
tories involved in clinical studies, and standards should
be in the clinically informative range (able to show that
quantitation or other analysis is accurate and reprodu-
cible at the cut-off level). As noted above, the assays
selected should already have published performance data
with a known performance at the level that is appropriate
for use in clinical trials; depending on the technology,
there should also be independent analytical validation for
different organ systems. The effects of pre-analytical vari-
ables related to biospecimen acquisition, processing, and
transportation should be predetermined for each assay
type and serve as the evidence base for standardized pro-
cedures to obtain and handle assay samples. Each assay
should demonstrate a relevant dynamic range in response;
where appropriate, the assay should provide capabilities
for identifying biologically relevant point mutations and
ideally capture viable cells for additional analyses. Each
testing laboratory needs to validate the assay using the
manufacturer’s published data as guidance in developing
internal validation criteria.
Standards
Workshop participants and the CWG strongly endorsed
the development of standard language for describing
CTCs and of standard operating procedures (SOPs) for
clinical evaluation of CTC assays prior to any testing on
patient specimens. For example, different CTC subtypes
may need to be defined, and the definitions should be
context-dependent. Creating a panel of criteria for de-
scribing CTCs that together can provide statistical confi-
dence provides an alternative approach.
Pre-analytic protocol standards for acquiring, handling,
and transporting samples, and acquiring, processing, and
interpreting assays are needed to allow collaboration
among centers at a level of detail sufficient to encompass
all likely variables. These standards should enable com-
parisons across platforms, contexts of use, and time.
Efforts should be made to develop protocols for evaluat-
ing technologies that are uniform and clinically meaning-
ful with regard to well-defined parameters for specific
applications. Though ideally flexible enough so that new
technologies can be easily integrated, the standards
should be evaluated rigorously.
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Table 2 CTC Assays and Technologies
Assay/Technology Name Manufacturer/Developer Assay Outcome Target Cancer(s) Technology/Process
AdnaTest AdnaGen, Langenhagen, Germany Enrichment/Characterization Breast, Prostate, Colon Immunomagnetic-based EpCAM enrichment
using labelled beads incubated with the
whole blood sample. Unlabeled cells are
removed; labelled cells are then lyzed. RNA is
isolated, followed by multiplex RT-PCR
(GA733-2, HER2, MUC1) to detect specific
tumor biomarkers.
Anti-EpCAM/Anti-CK
Antibody CTC Enrichment
Glenn Deng, Stanford
University, Stanford, CA
Enrichment/Enumeration Metastatic Breast Cancer CTC enrichment assay using the combination
of anti-CK and anti-EpCAM antibodies. Image
analysis performed using the AriolW system.
CTC identification with brightfield and
fluorescence labelled anti-CK,
anti-CD45, and 4′,6-diamidino-2-phenylindole
(DAPI) images.
ApoStreamTM ApoCell Enrichment Prostate, Lung Isolation of CTCs in a whole blood sample
using dielectrophoretic field flow fractionation
(DFFF), which separates cells based on
differing dielectric properties. See also DFFF
technology entry below.
autoMACS/MACS (Magnetic
Activated Cell Sorting System)
Mitenyi Biotec, Bergisch
Gladbach, Germany
Enrichment ———————— Utilizes an immunomagnetic column to
capture cells with various antigens (EpCAM,
pan-CK, HER2/neu, or CD45). Manual or
semi-automated system. These viable cells are
available for subsequent analysis following
enrichment.
Bioflux Fluxion Biosciences, South
San Francisco, CA
Enumeration ———————— Well Plate Microfluidic™ technology to obtain
physiologically-relevant data from cell-based
assays. Data acquisition obtained in brightfield,
phase, fluorescence, and confocal
high-resolution microscopy.
CEER (Collaborative Enzyme
Enhanced Reactive) Immunoassay
Prometheus Laboratories Inc. Characterization ———————— Multiplexed protein microarray platform that
measures the expression and activation of
specific cancer pathways with high levels
of sensitivity and specificity.
Bayer Schering Pharma AG,
Germany
CELLection™ Epithelial Enrich Traci Libby, Invitrogen,
Carlsbad, California
Enrichment ———————— Positive isolation. Obtain up to 5 log
enrichment of viable epithelial tumor cells
that are suitable for immunocytochemical
staining or any other downstream
application.
CellSearch™ Veridex Enrichment/Enumeration Metastatic Breast, Colon,
Prostate, Lung, Melanoma,
Urothelial Cancer
Automated immunomagnetic enrichment
and staining system for quantification of
CTCs in whole blood samples. CTCs
are enriched using ferrofluids coupled to
anti-EpCAM antibodies and identified by
cytokeratin staining using fluorescent
anti-CK antibodies, as well as counterstaining
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Table 2 CTC Assays and Technologies (Continued)
with anti-CD45 antibodies. Currently, the
only diagnostic test cleared by the FDA.
ClearCell System (CTChip and
Clearcell Unit)
Clearbridge Biomedic, Singapore Enrichment ———————— Detects and isolates intact, viable CTCs
from small quantities of whole, unprocessed
blood. Isolated CTCs can then be stained
directly on the CTChipW for identification,
or retrieved for further molecular analysis.
CTC Chip Dan Haber and Mehmet
Toner, Dana Farber and MGH,
Boston, MA
Enrichment/Enumeration Breast, Colon, Lung,
Prostate, Pancreas
Enrichment using microfluidic technology—
whole blood is pumped across a
silicon-etched chip that contains 78,000
microposts fitted with anti-EpCAM antibodies.
EpCAM-positive cells attach to the microposts
and are then detected by a camera. Includes
a chamber to enclose the fluid and chip and
a pneumatic pump.
Developers:
On-Q-ity, Waltham, MA
ICx Biosystems, San Diego, CA
Johnson & Johnson
CTC Membrane Microfilter Richard Cote, Ram Datar,
University of Miami, FL
Enumeration Prostate Stepwise photolithography process that
produces controlled-size pores designed to
exploit cell size differences between tumor
and normal blood cells. Combined with
quantum dot-based immunofluorescence
detection for CTC characterization.
Cytoscale CTC Assay Hsian-Rong Tseng, University
of California, Los Angeles
Enumeration Prostate, Breast, Colon
and Kidney
Antibody cell-surface marker capture
enhanced by nanostructures;
immunohistochemistry staining for cell
identification.
DEPArray Nicolo Manares, Silicon Biosystems,
SpA, Bologna, Italy
Enumeration ———————— Cell microarray for individual cell
manipulation and detection. The base is
a microelectronic active silicon substrate
embedding control circuitry for addressing
each individual dielectrophoretic (DEP)
cage (cage size can be set to accommodate
a single cell). The system allows detection
and sorting of rare cells and sorting by
morphological parameters such as shape,
nucleus-to-cytoplasm ratio, fluorophores
co-localization (by image-based selection).
Dielectrophoretic Field
Flow Fractionation(DFFF)
Peter Gascoyne, MD Anderson
Cancer Center, Houston, TX
Enumeration ———————— Cell-separation technique that exploits the
differences in density and dielectric properties
of cells to aid isolation of CTCs from clinical
blood specimens. See also ApoStream™
assay above.
Dylight Technology Medical University Graz, Austria Enumeration Breast Immunofluorescence method for identifying
CTCs that utilizes staining for multiple
markers, including CD44, ALDH1, and CK
using DyLight dyes; and subsequent analysis
by novel DyLight technology.
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Table 2 CTC Assays and Technologies (Continued)
DynabeadsW CD45 Traci Libby, Invitrogen,
Carlsbad, California
Enrichment ———————— DynabeadsW are coated with anti-CD45
monoclonal antibody for efficient depletion
of human leucocytes in whole blood samples
to enrich epithelial tumor cells.
DynabeadsW Epithelial Enriched Traci Libby, Invitrogen,
Carlsbad, California
Enrichment ———————— DynabeadsW are coated with the monoclonal
antibody BerEP4 against the human epithelial
antigen, EpCAM. Enriched tumor cells are
lysed for mRNA isolation and RT-PCR
amplification.
Epic HD-CTC Assay Epic Sciences, Inc. Enumeration/Characterization Prostate, Breast, Pancreas CTC detected in peripheral blood through
red blood cells lysis and fluorescently
labeled antibodies. See also FAST
Cytometer entry.
EPISPOT (EPithelial ImmunoSPOT) Catherine Alix-Panabieres and Klaus
Pantel, Laboratoire de Virologie,
Hôpital Lapeyronie, CHU Montpellier,
France & UKE, Hamburg, Germany
Characterization Breast, Prostate, Colon After depletion of CD45 positive cells,
remaining cells in a whole blood sample
are cultured for 24 hours on a membrane
coated with antibodies that detect proteins
shed from viable CTCs by secondary
antibodies labelled with fluorochromes.
FAST Cytometer(Fiberoptic
Array Scanning Technology)
Peter Kuhn, Scripps Institute, La Jolla, CA Enumeration/Characterization Metastatic Breast Cancer Fluorescence cytometry combined with an
automated digital microscopy imaging
system. Immunofluorescently labelled
CTCs are detected on a glass slide using
laser-printing optics, which can scan
300,000 cells per second. See also Epic
HD-CTC Assay entry.
Robert Bruce, Scripps Palo Alto Research
Center, Palo Alto, CA
Flow Cytometry Jeannie Gaylor, Becton-Dickinson,
San Jose CA
Enrichment/Enumeration ———————— Multiple reagents and systems adaptable
to analysis or sorting of CTCs.
HB-CTC (Herringbone-Chip) Mehmet Toner and Daniel Haber,
Massachusetts General Hospital (MGH)
and Harvard Medical School
Enrichment/Enumeration ———————— A high-throughput microfluidic mixing
device which provides an enhanced platform
(over the CTC-chip) for CTC isolation where
microvortices are utilized to significantly
increase the number of interactions between
target CTCs and the antibody-coated chip
surface.
ISET (Isolation by Size of
Epithelial Tumor cells)
Metagenex, Paris, France Enrichment ———————— CTCs are separated from other cells in whole
blood by size via vacuum filtration. This
technique is gentle and produces viable cells
that can be further analyzed following
enrichment.
IsoFlux™ Rare Cell Access System Fluxion Biosciences, South
San Francisco, CA
Enrichment ———————— Proprietary microfluidic technology to isolate
rare cells with high efficiency. The system
incorporates CellSpot™ Technology to
produce a highly concentrated sample that is
optimized for downstream molecular analyses.
Laser Scanning Cytometry Maintrac, Bayreuth Germany Enumeration/Characterization Breast, Colon, Prostate,
Sarcoma
Custom laboratory analysis service performed
on slides using a variety of fluorochrome-
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Table 2 CTC Assays and Technologies (Continued)
labelled antibodies or other techniques
(e.g., estrogen receptor, HER2,
prostate-specific antigen, FISH, terminal dUTP
nick end labelling). Traceable single cell
detection within 1 million cells.
Laser Scanning Cytometry (LSC) ApoCell Enumeration ———————— Proprietary microscope-based
immunofluorescent image analysis.
Lymphoprep™ (Ficoll-Isopaque) Axis-Shield PoC, Oslo, Norway Enrichment ———————— Separates mononuclear cells from other
cells in whole blood based on cell density.
MagSweeper Stephanie Jeffrey and Ronald W. Davis,
Stanford University, Stanford, CA
Enrichment/Enumeration Metastatic Breast Automated immunomagnetic
enrichment-gently enriches target cells
and eliminates cells that are not bound to
magnetic particles. Isolated cells can be
extracted individually based on their physical
characteristics to deplete any cells
nonspecifically bound to beads. Processes 9 mL
of blood per hour and captures >50% of
circulating epithelial cells as measured in
spiking experiments.
Multiphoton Intravital
Flow Cytometry
Philip Low, Purdue University,
West Lafayette, IN
Enumeration Prostate Noninvasively counts rare CTCs in vivo as they
flow through the peripheral vasculature.
The method involves intravenous injection of a
tumor-specific fluorescent ligand followed
by multiphoton fluorescence imaging of
superficial blood vessels to quantitate the
flowing CTCs.
Nanodetector Gilupi, Potsdam, Germany Enrichment/Enumeration Breast, lung, prostate The nanodetector (functionalized structured
medical wire, FSMW) is inserted into the
patient’s arm vein via a standard 20-gauge
needle. The nanodetector consists of a medical
stainless steel wire, coated with a gold layer
and a hydrogel functionalized with an
anti-EpCAM antibody. During the 30 min
application in the vein, up to 1,500 mL of blood
including the respective CTC pass the
nanodetector and enable a high number of CTC
to be bound by the anti-EpCAM antibody.
Negative Enrichment OMS Jeffrey Chalmers, Cleveland Clinic,
Cleveland, OH
Enrichment/Enumeration Head & Neck, Breast Red cell lysis, immunomagnetic labelling and
subsequent depletion of CD45+ cells
(leukocytes). Remaining cells may be further
characterized (epithelial cells, cells
undergoing EMT).
PerCelleon, LLC
Stem Cell Technologies
Nucleopore Assay Whatman International Ltd., UK Enrichment ———————— CTCs are separated from other cells in whole
blood by size via vacuum filtration.
OncoCEE-BR™ Biocept, Inc. and Clarient, Inc. Enumeration/Characterization Breast OncoCEE™ captures CTCs via a microfluidic
system that uses multiple antibodies for
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Table 2 CTC Assays and Technologies (Continued)
capture followed by detection using
CEE-Enhanced staining and then detects their
HER2/neu status via FISH.
OncoQuick Greiner Bio-One, Germany,
North Carolina
Enrichment Breast, Colon, Others Centrifugal separation using optimized liquid
media based on tumor cell buoyant density
only. Achieves enrichment of up to 6 logs from
approximately 104 total mononuclear cells.
Validated with spiking studies.
Optofluidic Intracavity
Spectroscopy (OFIS)
David Kisker eOptra, Longmont, CO Enumeration ———————— OFIS has been used to investigate the
properties of several tumor cell lines and
compared the results to cells from peripheral
blood. The results suggest that a unique
optical signature may be a characteristic of
many tumor cells. This signature may offer a
complementary tool to molecular methods
for detection and enumeration of CTCs. In
addition, by using dielectrophoresis to trap
and steer cells, it is possible that induced
changes in the OFIS spectrum may detect
other characteristics of tumor cells, as well
as transport and sort them according to
those characteristic properties.
Photoacoustic Detection John Viator, University of Missouri,
Columbia, MO
Enumeration Melanoma, Breast Cancer Flowmetry system in which blood samples
are irradiated with laser light, and
photoacoustic waves from cancer cells are
detected and counted (uses melanin in
melanoma, gold-tagging of other cancer cells).
RARE (RosetteSep-Applied
Imaging Rare Event)
StemCell Technologies, Vancouver, BC Enrichment ———————— Negative selection technique where
tetrameric antibody complexes crosslink
CD45-expressing leukocytes to red blood
cells in whole blood. These complexes pellet to
the bottom of the tube when centrifuged
due to increased density, enriching
CD45-negative cells (CTCs).
RoboSep/EasySep™ Stem Cell Technologies, Vancouver Enrichment Myeloma, Epithelial Tumors,
CD45 depletion
Immunomagnetic nanoparticle-cell complexes
are captured in tubes and unlabeled cells
are poured off. Adaptable to custom CTC
antibody surface antigens. Manual or
semi-automated systems.
ScreenCellW Cyto, ScreenCellW
CC, ScreenCellW MB
ScreenCell Company Biopark 12 rue
J-A de Baïf 75013, Paris
Enrichment ———————— The ScreenCellW Cyto device isolates rare
tumor cells, with a high recovery rate. The
ScreenCellW CC device allows isolation of
either fixed or live cells. Fixed cells are well
preserved morphologically.
Immunocytochemistry and FISH assays can be
performed directly on the filter. Isolated live
cells are able to grow in culture. High-quality
genetic materials (DNA, RNA) can be obtained
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Table 2 CTC Assays and Technologies (Continued)
directly from tumor cells isolated on the
ScreenCellW MB device filter. The ScreenCellW
devices may be able to simplify and improve
noninvasive access to tumor cells due to their
reduced size, versatility, and capacity to isolate
CTCs within minutes.
Single Cell Gene Expression with
BioMark™ Real-Time PCR System
Fluidigm Corporation, South
San Francisco, CA
Characterization ———————— Allows high-throughput cell-line studies to
determine individual cell behavior and is
suited to determine single-gene cell expression
levels in CTCs. Results are presented as a heat
map, with individual assays on the X-axis and
individual cell samples on Y-axis. The
intersection of each assay and sample is an
individual real-time qPCR reaction.
Supervised* Automated Microscopy Iqbal Habib, Ariol, Genetix, Boston MA,
San Jose CA
Enumeration/Characterization Breast, Others? Commercial component to automatically track,
review, and enumerate immunocytochemically
stained candidate CTCs. Nuclear, shape factor
morphology image analysis system with
computer display.
TelomeScan (OBP-401) Oncolys BioPharma, Tokyo Enumeration/Characterization Gastric, Breast Uses a virus vector for CTC detection. The virus
is incubated with whole blood sample for 24 hrs
and replicates with cancer cells, incorporating
the GFP marker into them. CTCs are then
detectable by fluorescence system analysis of
cell preparation on slide. Potential for in vivo
transfection and detection of GFP+CTCs in
capillary bed of patient.
Vita-Assay[Functional Collagen
Adhesion Matrix (CAM)]
Wen-Tien Chen, Vitatex, Stony
Brook, NY
Enumeration Prostate CAM ingestion. Enables molecular
characterization of captured cells.
(Commercial and Being Developed for Commercial Application).
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While specific procedures for sample acquisition, hand-
ling, and processing should probably be dictated by the
analysis to be done, general recommendations for sample
handling should be made. Pre-analytical variables, includ-
ing fasting status, time of day, body positioning during
the blood draw, and venipuncture needle size should be
standardized. It also may be desirable for CTC assay plat-
form companies to supply completely self-contained col-
lection kits to minimize the pre-analytic variability.
Procedures for handling acquired samples, including sam-
ple transport and storage, should also be standardized
and deviations tracked variables related to sample collec-
tion and analysis are listed following:
Materials at Site
 Sample collection kit with instructions for use
 Shipping container
 Temperature monitoring strips
Materials at Lab
 Appropriate analytical instrumentation
 Analytical reagents
 Standards
 Multiple levels of controls
Precollection Variables
 Reagent storage temperature
 Reagent storage time
 Patient preparation—for example, fasting status
Sample Collection Variables
 Timing of sample collection in study protocol
 Sample collection method
 Number of specimen collected, including duplicates
 Subject positioning during sample collection
 Specimen transport time
 Specimen storage temperature
 Specimen storage time
 Assay-specific SOPs
 Lot-specific control testing
 Levels of quality control testing (daily, monthly)
 Lab certification
 Assay platform training
All testing should use rigorous criteria such as Clinical
Laboratory Improvement Amendments (CLIA) or good
laboratory practice (GLP) standards. Early-stage develop-
ment studies of clinical assays are not subject to CLIA
regulation; however, clinical trials where biomarker
assays are integral to the design need to be done in
CLIA-certified laboratories, and if the results of the
assay are used to make treatment decisions, FDA review
is generally needed. Biomarker assays are considered to
play an integral role when done in real time and the
results used for trial eligibility or to make individual pa-
tient decisions—for example, to stratify patients, assign a
patient to a specific treatment arm, or decide whether to
escalate dose or stop treatment [58].
The fragility/lability of tumor cells introduces an im-
portant source of variability in the evaluation of CTC
assay platforms that analyze captured whole cells, since
CTC apoptosis begins very early after separation from
the tumor of origin and after removal of blood from the
patient [59-61]. Incorporating cellular preservatives in
the collection of peripheral blood samples has been
shown to stabilize CTCs for up to 96 hours [25,32,61].
Standard use of this procedure would allow greater flexi-
bility in sample storage and shipping, which in turn may
allow the inclusion of more enumeration assay technolo-
gies in comparison evaluations, and make their
utilization in the clinic more practical.
Archived CTC samples may be adequate for
molecular-based assays, assuming that one is able to
demonstrate that the cells of interest have survived the
archiving procedure and duration in numbers and
Table 3 CTC Assay Clinical Readiness Evaluation
Assay Validation
Pre-Analytic How is specimen collected (venous route, body
position, draw order, tourniquet time, needle bore,
tube type)?
When is specimen collected (time of day, relative to
treatment, relative to infusates)?
How is specimen stored (time and temperature)?
How is specimen handled (shipping, transfers)?
Analytic Sensitivity (lower limit of quantitation)?
Reportable range?
Specificity?
Reproducibility?
Robustness?
Post-Analytic How is data reported?
How is data analyzed?
What are the reference intervals?
Clinical Feasibility
• Are there analytically valid results when tested in appropriate
preclinical models?
○ with use of clinically relevant/feasible specimen acquisition?
○ with use of clinically relevant specimen handling procedures
(both at the point of acquisition and in the receiving laboratory)?
These processes should be tracked and recorded.
○ with use of clinically relevant collection scheduling?
Therapeutic Relevance
• For predictive biomarkers, is there a relationship between dose/
exposure, quantifiable target modulation, and disease outcome?
• For prognostic biomarkers, is there a relationship between baseline
levels and survival?
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biological condition that represent their state when col-
lected. However, access to systematically collected and
appropriately well-preserved patient samples with linked
clinical outcome data is essential [62]. For CTC studies
in general, archived tumor samples may be difficult to
obtain, suboptimal for certain molecular assays, or not
representative of a patient’s disease at the time of treat-
ment. The NCI has provided detailed recommendations
related to biospecimen and data quality in the 2010
Revised NCI Best Practices. The NCI Office of Bioreposi-
tories and Biospecimen Research (OBBR) is one resource
for well-defined archived samples that are collected using
the most stringent SOPs.
Established in 2005, a goal of OBBR is to develop a
common biorepository infrastructure to facilitate multi-
institutional genomic and proteomic studies. Partnering
with an organization like OBBR to develop CTC-specific
SOPs, as well as a source of clinical samples for assay
comparison studies, should be considered.
Initial interassay comparison on clinical samples
For most new CTC technologies reviewed, it was noted
that too little systematically collected data were available
to allow evaluation of potential clinical utility or to com-
pare with other assays. Beyond analytical validity, foun-
dational data on the individual assays are needed, such
as frequency of detection in specific patient populations
and consistency of the results in a given patient in deter-
minations on multiple days and at different time inter-
vals, as well as the capability for detecting quantifiable
changes to a patient’s results after appropriate treatment.
Specificity of a CTC assay depends on a particular test
result representing the target tumor cells, as opposed to
normal hematopoietic or circulating epithelial cells. This
distinction can often be made by either visual inspection
by a trained cytopathologist or by determination of mo-
lecular markers, or a combination of these techniques.
For example, Meng et al. have demonstrated that in
patients with metastatic breast cancer, epithelial cells
identified using an immunomagnetic separation system
with anti-EpCAM as the capture antibody are highly
aneusomic and almost certainly malignant and not nor-
mal [60]. Further, Shaffer et al. demonstrated that cells
captured by CellSearch™ expressed prostate specific anti-
gens and had molecular features of malignancy as deter-
mined by FISH analysis [38].
However, it is conceivable that not all cells that meet
visual or molecular criteria for cancer have true malig-
nant potential or, conversely, that not all cells lacking
the defined criteria are nonmalignant (e.g., [24,63]).
Current thought is in part based on stem cell theory,
which posits that only a fraction of any tumor mass, and
therefore of any CTC population, is able to establish and
maintain a metastasis. Also as suggested above, it is
known that many cells identified in the circulation are
already undergoing, or have completed, apoptosis.
Therefore, biologic relevance is not just the presence of
unequivocally malignant-appearing cells, but the bio-
logical and/or clinical significance of these cells. The lat-
ter can only be determined by correlating the presence
of assay metrics (presumed CTCs) with some clinically
or biologically important outcome, such as tumor re-
gression, subsequent recurrence, new primary cancer, or
death.
The implication of biologic significance is that one
cannot conclude that a new assay is superior to a gold-
standard assay by mere comparison of assay metrics/unit
blood between the two. One must determine whether a
presumably more sensitive assay retains, or exceeds, the
robust separation of outcomes between patients who are
positive vs. those who are negative for the assay, and this
can only be demonstrated in well-designed clinical
studies.
Direct comparison of different technologies on the
same clinical samples and/or in tumor cell spiking
experiments would be informative. One or two specific
CTC-derived biomarkers (e.g., EpCAM) could be used to
identify the optimal assay technologies. Gold-standard
technologies are needed for comparisons, based on
whether the evaluation is quantitative (enumeration of
CTCs) or qualitative (molecular characterization of
CTCs). CellSearch™ could serve as an anchor in the
short term for assessments of newer enumeration assay
technologies, building on prior clinical evidence for its
predictive and prognostic capability.
The CWG discussed approaches to carry out this
evaluation in which the Biomarkers Consortium would
provide a framework wherein laboratories studying the
selected technologies would have access to matched pre-
and post-treatment clinical samples from multiple clin-
ical settings as obtained by the OBBR or an equivalent
source. The samples could be from patients treated with
approved therapies (e.g., the control arms of randomized
clinical trials), well-annotated regarding patient charac-
teristics and outcomes, and collected and processed
according to standard protocols as described above.
Fresh blood samples may be needed for these studies
since archived samples may contain degraded cells and
no longer reflect the disease state of the donor at the
time of collection. The samples could be analyzed by
multiple methods, would be blinded to the analyzing la-
boratory, and results data would be compiled by the
CWG prior to release back to the assay developer. This
approach would yield information regarding whether dif-
ferent technologies are detecting different CTC popula-
tions and provide information for definitions of
analytically valid biomarkers that may need to be estab-
lished for these different populations.
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Clinical trial design considerations
Despite the fact that research aimed at defining and
understanding the biology of CTCs is still ongoing and
many promising assays are still early in development, the
Workshop participants and CWG believe that it is crucial
to establish clinical validation and qualification trials soon
with the goal of determining the true clinical relevance of
CTCs and specific assays of CTCs. In this regard, the ex-
cellent on-going qualification work in collaboration with
FDA regarding the use of CTCs as an efficacy response
surrogate biomarker for survival in patients with advanced
prostate cancer [38,43] was acknowledged.
Beyond clinical validation of specific assays, CTC
qualification studies should initially seek to answer clin-
ically relevant questions, such as a) to determine the po-
tential utility of CTCs in early clinical development of
drugs (phase 1 and 2 trials); b) to determine if enumer-
ation could be an early efficacy response marker; c) to
help drive the use of enumeration as a surrogate marker
of response to therapy; d) to investigate whether CTC
evaluations could augment or replace imaging for re-
sponse monitoring; and e) to investigate whether the
molecular analysis of CTCs could replace tumor biopsies
for patient stratification for targeted therapies. In the
short term, there is general interest in the application of
CTC enumeration for determining response to therapy;
therefore, association of CTC measurements with
complete response, partial response, stable disease, and
progressive disease would be appropriate endpoints for
initial clinical trials.
Several trial designs may be useful in addressing these
questions regarding evaluation of clinical validity of
CTC technologies and qualification of CTC measure-
ments as biomarkers of response to therapy. First, CTC
substudies may be added to ongoing trials where the
study treatment choices and primary endpoints (early
endpoints such as objective response, as well as clinical
outcomes) would be dictated by the parent trial. Single-
arm studies could be used to explore changes pre- and
post-therapy and correlation with outcomes, thus assist-
ing with determining cut points. As single-arm trials can
only evaluate prognostic potential, two-arm, two-drug
substudies could also be used to compare results with
different therapies to evaluate the predictive potential of
CTCs. Alternatively, the CTC study may be fully inte-
grated into the trial design. In this design, patients
would be randomized on the basis of the presence or ab-
sence of CTCs. The FDA has recommended this study
design to evaluate diagnostic tests for use in the selec-
tion of drug therapy.
One example of an ongoing clinical trial to test the
clinical utility of CTCs is SWOG S0500. In this trial,
women starting a first line chemotherapeutic regimen
for hormone-refractory metastatic breast cancer and
who have persistently elevated CTCs after one cycle are
randomly assigned to continue their therapy until classic
evidence of progression (history, physical examination,
imaging) or to change immediately to a different regi-
men. The goal of this study is to demonstrate an
improved overall survival for women who are switched,
based on a CTC test result (see Figure 1) [64], from an
apparently ineffective treatment strategy to an alterna-
tive one. Patient populations where treatments have the
potential to change based on the results of the trial
should be targeted. The cohorts should include patients
with measureable, advanced, non-hematologic cancers,
as currently the most interesting and appropriate clinical
application of CTC analysis is to establish its predictive
value for response to therapy.
In terms of study indication, there should be no bias
for target tumors other than the robustness of the avail-
able data. Robust CTC data have been obtained with the
CellSearch™ System for breast, colorectal, and prostate
disease. With the same technology, low numbers of
CTCs are captured in the metastatic settings for colon
and lung cancer; therefore, newer technologies with
higher sensitivity and good specificity rates may be use-
ful in these settings. In early disease, such as neoadju-
vant settings, where fewer CTCs are expected [8,9,65], a
potential benefit of more sensitive assays could be a
shorter timeframe to analysis of study endpoints like the
extent of residual disease after surgery as an early mar-
ker of outcome, which provides value for new drug de-
velopment. In addition to more efficient enumeration,
newer technologies provide the promise of molecular
profiling of tumor response to therapy in all the clinical
designs described.
A clinical validation and qualification study strategy and
process
The CSC of the Biomarkers Consortium is interested in
supporting a series of studies to help resolve important
pre-competitive issues around CTCs, with the overall
objectives of providing evidence toward qualification of
CTC derived biomarkers for assessing prognosis pre-
therapy, establishing CTC number as a surrogate for
survival, and determining whether the molecular profile
of CTCs predict response to treatment.
The initial goal of the proposed strategy will be to
demonstrate the robustness of candidate CTC assay
technologies currently under development, prior to clin-
ical studies, in order to determine which of the plat-
forms are closest to being ready for validation in the
clinical trial setting. The proposed studies will evaluate
newer CTC enumeration assays considered to be the
most promising technologies using criteria created by
the CSC and CWG against the FDA-cleared analytically
valid CellSearch™ assay. The most promising CTC
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SCHEMA
* Patients must be registered prior to initiation of testing (no more than one working day 
prior to initial CTC submission).
** Patients in the Low Risk Group (Arm A) may enroll in other clinical trials while being 
followed for OS and PFS on S0500.
*** Patients in Arms B and C1 and their physicians will be blinded to which arm they are by 
study design. Protocol requirements are the same for these two arms.
Registration
*Screening blood draw prior to first dose of first- line chemotherapy
Chemotherapy may be initiated while waiting for CTC result
**Follow-up for OS and PFS
No further blood draws
2nd blood draw 
at Day 22
<5 CTC/7.5 mL
Arm B (Moderate Risk)
Randomization
Arm C (High Risk)
***Arm B           ***Arm C
Maintain Current Therapy Group
Arm C2
Switch Therapy Group
<5 CTC/7.5 mL blood
Arm A (Low Risk)
mL
Figure 1 Schema of Southwest Oncology Group (SWOG) Study S0500. This clinical study is evaluating the use of CTC levels in managing the
treatment of metastatic breast cancer patients. Baseline CTC levels are determined using the CellSearch System™. Patients with CTC levels <5
CTCs/7.5 ml receive no further therapy, but are followed for progression-free survival (PFS) and overall survival (OS) (Arm A). For the remaining
patients (≥ 5 CTCs/7.5 ml blood), CTCs are measured at specified time points during the course of chemotherapy. Patients with <5 CTCs/7.5 ml
blood at 22 weeks continue with their current chemotherapy (Arm B). Patients with ≥5 CTCs/7.5 ml blood at this time point are randomized to
current therapy (Arm C1) or a different therapy (Arm C2). Patients are followed for PFS and OS. (Reprinted by permission from the American
Association for Cancer Research: Hayes DF, Smerage J: Is there a role for circulating tumor cells in the management of breast cancer? Clin Cancer
Res 2008, 14 (12):3646–3650 DOI:10.1158/1078-0432.CCR-07-4481. See reference [64]).
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molecular characterization assays will also be compared
using these criteria. Additionally, recognizing the need
for standardizing procedures for specimen collection
and processing to ensure the reliability of CTC measure-
ments, the CWG will develop these procedures for CTC
assays evaluated in this project. A small pilot in this re-
gard was recently presented at an OBBR symposium,
where CSSI, Offices of Physical Sciences-Oncology
(OPSO), and OBBR are collaborating to examine the po-
tential of using high-content systems to measure the ef-
fect of pre-analytical variables on biophysical parameters
associated with biospecimens.
For cell spiking experiments, cell lines considered ap-
propriate for the selected technologies will be obtained
and cultured in standard conditions. Fluorescent label-
ling of target cells will be performed using standard cell
labelling kits. Multiple samples from a given cell suspen-
sion will be counted and averaged to produce a mean
cell count with a small standard deviation in order to
minimize counting errors. The cell suspensions will then
be appropriately diluted and processed using the selected
CTC assay technologies. Capture efficiency percentages
will be calculated using criteria as defined by the CWG.
In clinical studies, triplicate specimens will be col-
lected from subjects participating in ongoing studies
with relevant indications and study populations in order
to compare the candidate assays against each other. For
the CTC enumeration studies, one of each set of three
samples will be analyzed using the CellSearch™ assay.
Similarly, for the CTC molecular characterization stud-
ies, one assay will be selected to be used as the anchor.
All clinical samples will be procured through the OBBR,
or using SOPs compliant with OBBR requirements.
In the clinical validation studies, CTC substudies will
be conducted in prospective phase 2 or 3 clinical trials
(or if the assays selected do not require fresh blood,
archived samples will be accessed from completed pro-
spective studies for retrospective analysis) in an attempt
to correlate CTC measurements with clinical outcomes
related to treatment response, and time-related out-
comes such as time to progression or disease-free sur-
vival. Here, duplicate specimens will be collected. The
CTC assays will be performed pre-therapy and at
defined intervals post-therapy on anonymized patient
samples collected in the trial, blinding technicians to any
patient identifiers. The specimens will be collected at
participating sites and forwarded to the specified clinical
laboratories for processing. In addition to SOPs for vari-
ables associated with sample collection as outlined above
standard protocols are needed to allow comparison of
CTC assay results across technology platforms. Just as
challenging is the development of standards for collect-
ing certain data points to analyze after advances have oc-
curred in the field, so comparisons could be made over
time. The standards would have to be flexible to easily
incorporate new technologies.
After performing clinical validation studies, the next
stage, qualification, would be follow-on clinical studies to
determine the context-of-use of specific CTC measures.
These studies will most likely be conducted in the phase
3 metastatic disease trial setting for specified indications
in specified study populations. Baseline CTCs would be
assessed, and then additional assessments would be made
at some point after the start of treatment. These assess-
ments may be used to determine the role of CTC analysis
for monitoring disease recurrence, evaluating new treat-
ments against standard therapy, or investigating concord-
ance between imaging and CTC analysis. If a series of
studies with clinical benefit outcomes shows good correl-
ation and reproducibility between a given CTC measure
and survival, that biomarker could be considered a candi-
date for FDA qualification.
Conclusions
Without question, the Veridex CellSearch™ assay and the
advanced technologies now being applied to CTC detec-
tion and analysis have high promise for providing bio-
markers and biomarker assays useful in oncological drug
development, monitoring the course of disease in cancer
patients, and in understanding the biology of cancer pro-
gression. However, many questions remain unanswered
regarding the biology of CTCs, best methods for their
enumeration and characterization, and the path to regu-
latory and general clinical acceptance for technologies
currently under development. Standard protocols for ac-
quisition and processing of blood samples, as well as
sources of well-annotated clinical samples (including
clinical outcomes) and application of criteria for analyt-
ical and clinical validation of CTC assays and qualifica-
tion of CTC-based biomarkers are mandatory for the
next steps in evaluation of these technologies. Develop-
ing and applying these standards is difficult, if not im-
possible, for individual research institutions and
companies; this effort requires coordinated clinical trial
resources for obtaining samples and infrastructure for
developing standards, managing the collection and dis-
tribution of samples, and evaluation of test results, as
well as input from engaged scientists and the FDA. To
this end, the Biomarkers Consortium, as a public-private
partnership, is proposing and planning to implement the
framework described in this review.
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